Biotech VC Woes Really Demand Growth, Not Supply Shortfall

Feb 27, 2012, 01:15 AM by Michael Croft

Pharmalot | Conventional wisdom says that biotech is a tough sell for venture capitalists these days, but new analysis shows a 16% increase over VC funding in 2011 compared to 2010, and a stunning 90% increase year to year in the last quarter.

February 27, 2012 | Conventional wisdom says that biotech is a tough sell for venture capitalists these days, but new analysis shows a 16% increase over VC funding in 2011 compared to 2010, and a stunning 90% increase year to year in the last quarter. In fact biotech raised more than medical device makers or diagnostic companies. Why the perceived supply issues? A real increase in demand. Pharmalot